Chagas disease is a protozoan infection which was first identified more
than one hundred years ago. But even now, drugs to
treat the latent and chronic phases of the disease are not available.
The success of a drug design is highly dependent on activity and
toxicity. In the case of Chagas disease, questions remain as to
identifying the best treatment (mainly for the chronic phase), and how
new drugs and drug combinations compare to current therapy. The
principal priority of this mini-review is to report the enormous
difficulty that pharmaceutical chemists encounter in the development of
new drugs for neglected tropical infectious diseases, in this
case Chagas disease.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.